Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 06, 2021 08:35 ET | Source: Precision Biosciences

Precision BioSciences Announces CEO Transition Plan

DURHAM, N.C., April 06, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
March 29, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences to Participate in the Guggenheim Healthcare Talks 2021 Genomic Medicines & Rare Disease Day

DURHAM, N.C., March 29, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
March 18, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences Reports Fourth Quarter and Fiscal Year 2020 Financial Results and Provides Business Update

Established in vivo genome editing research collaboration and exclusive license agreement with Eli Lilly Reported interim data from Phase 1/2a study of PBCAR0191; updated interim data expected by...
March 12, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences to Report Fourth Quarter and Fiscal Year 2020 Financial Results on March 18, 2021

DURHAM, N.C., March 12, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company, today announced it will publish fourth quarter and fiscal year...
March 02, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences to Present at Upcoming Virtual Investor Conferences

DURHAM, N.C., March 02, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company developing allogeneic CAR T and in vivo gene correction therapies...
February 19, 2021 07:00 ET | Source: Precision Biosciences

Precision Announces 3-Year Pre-clinical Study Results Showing Long-term Durability and Safety of ARCUS In Vivo Gene Editing to Cut LDL Cholesterol Levels in Nonhuman Primates

DURHAM, N.C., Feb. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company, today announced the publication of a paper in Molecular Therapy...
February 04, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences to Present at Guggenheim Healthcare Talks 2021 Oncology Day

DURHAM, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its proprietary ARCUS® genome...
January 25, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences Receives Notice of Allowance for U.S. Patent Application Covering PBCAR19B, a Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

DURHAM, N.C., Jan. 25, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL) a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS®...
January 19, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences Announces FDA Accepts IND for PBCAR19B, a Next-Generation, Stealth Cell, CD19 Allogeneic CAR T Candidate for Non-Hodgkin Lymphoma

DURHAM, N.C., Jan. 19, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its wholly proprietary ARCUS®...
January 07, 2021 07:00 ET | Source: Precision Biosciences

Precision BioSciences Announces Closing of In Vivo Gene Editing Collaboration and License Agreement with Eli Lilly and Company

DURHAM, N.C., Jan. 07, 2021 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage biotechnology company dedicated to improving life with its novel and proprietary ARCUS®...

Next Page keyboard_arrow_right